Protein content and factor VIII complex in untreated, treated and monoclonal factor VIII concentrates.
Replacement therapy with clotting factor concentrates may expose the recipients not only to virus contamination but also to continuous stimulation of the immune system by repeated infusions of allogenic proteins. Concentrate purity is now a very important prerequisite to be taken into account in choosing what product can better meet the patient's needs. We compared protein content (albumin, fibrinogen, fibronectin, immunoglobulins) and factor VIII:C/vWF:Ag complex in untreated, treated and monoclonal factor VIII concentrates. Protein content is dramatically decreased in new treated ultrapure concentrates. Improved traditional fractionation methods allowed to obtain very high Factor VIII specific activity. New fractionation methods with immunoaffinity chromatography by means of monoclonal antibodies can give highly pure concentrates even if deliberately added albumin decreases factor VIII specific activity in final formulation. Otherwise monoclonal concentrates show a very high specific activity in terms of fibrinogen and immunoglobulin content, which, unlike albumin, are affecting the immune system in hemophiliacs.
Morfini
M
M
Hematology Department, University of Florence, Ospedale di Careggi, Italy.
Rafanelli
D
D
Filimberti
E
E
Cinotti
S
S
Piazza
E
E
Longo
G
G
Rossi Ferrini
P
P
D000911:Antibodies, Monoclonal; D001798:Blood Proteins / Q000032:analysis; D004340:Drug Contamination; D005169:Factor VIII / Q000302:isolation & purification*; D005340:Fibrinogen / Q000032:analysis; D005353:Fibronectins / Q000032:analysis; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D012709:Serum Albumin / Q000032:analysis; D014841:von Willebrand Factor / Q000032:analysis
D000911:Antibodies, Monoclonal; D001798:Blood Proteins; D005353:Fibronectins; D007136:Immunoglobulins; D012709:Serum Albumin; D014841:von Willebrand Factor; D005169:Factor VIII; D005340:Fibrinogen